ABOUT US

Afrigen Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalized by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa.

It was founded in 2014 by Steven G. Reed (PhD) and Erik Iverson (JD, LLM), both of the Infectious Diseases Research Institute (IDRI) www.idri.org in Seattle.

Afrigen drives a business strategy focussing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs.

Through international partnerships and local capacity building, Afrigen has established the first ever adjuvant production and formulation technology centre on the African continent.

This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value.

These adjuvants confer added potency and durability to vaccines. More recently, Afrigen has ventured into the novel CAM’s space where it aims to bring innovative, differentiated products to market.

OUR PRODUCTS AND SERVICES

PRODUCTS
  • Novel CAMS
  • Nanozomal CBD Products
  • Vaccines Adjuvants
  • Animal Health Products

 

SERVICES
  • Encapsulation Technologies 
  • Specialised Analytical Services 
  • Product Stability Performance
  • Afrigen Compounding Solutions

OUR LATEST NEWS

Please see below articles on where we have been featuring world wide. Be sure to visit our social pages for more updates.

| PRODUCT POST |

#CrampRelief by #afrigen 🔹If you’ve ever been awakened in the night or stopped in your tracks by a sudden charley horse, you know that muscle cramps can

Read More »